Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability
Table 1
Baseline patient and tumor characteristics in sorafenib treated HCC patients with corresponding median overall survival (mOS, days), 95% confidence intervals (CI), and values of the univariate analysis.
Characteristic
No. (%)
mOS (days)
95% CI
value
Gender
Male
59 (78)
150
112–188
0.207
Female
17 (22)
209
185–233
Age (median years)
63
31 (41)
176
112–239
0.799
≤63
45 (59)
153
117–188
ECOG performance status
0-1
59 (77)
186
57–170
0.005
2-3
16 (23)
54
20–109
Child-Pugh Class
A
43 (57)
191
168–214
<0.001
B
29 (38)
110
40–180
C
4 (5)
41
0–100
Portal vein thrombosis
Present
32 (42)
198
120–232
0.967
Absent
35 (46)
170
88–194
Unknown
9 (12)
217
138–174
Extrahepatic spread
Present
33 (43)
137
81–193
0.211
Absent
42 (55)
183
134–232
Ascites
Present
26 (34)
161
134–188
0.633
Absent
50 (66)
113
24–203
FP level (ng/mL)
≥200
26 (34)
160
110–210
0.016
200
56 (66)
178
122–234
Serum albumin (g/L)
≥35
39 (51)
186
169–203
0.003
35
36 (49)
92
26–158
Serum bilirubin (umol/L)
≥22
33 (43)
98
36–160
0.005
22
43 (67)
186
165–207
Serum lactatdehydrogenase LDH (U/L)
≥205
34 (50)
150
83–217
0.136
205
34 (50)
176
142–210
Comorbidity*
Presence of ≥1 substantial comorbidities
58 (76)
156
127–185
0.793
No comorbidity
18 (24)
191
28–354
Comorbidity assessed according to Charlson comorbidity classification.
